Development and validation of a highly sensitive LC–MS/MS-ESI method for quantification of IIIM-019—A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development-Reference-Cited by-同舟云学术

Development and validation of a highly sensitive LC–MS/MS-ESI method for quantification of IIIM-019—A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development

Published:2016-05 Issue: Volume:124 Page:26-33
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Kour Gurleen,Chandan Bal Krishan,Khullar Mowkshi,Munagala Gurunadham,Singh Parvinder Pal,Bhagat Asha,Gupta Ajai Prakash,Vishwakarma Ram A.,Ahmed Zabeer

Funder

Council of Scientific and Industrial Research

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference26 articles.

1. Global Tuberculosis Report;World Health Organization,2013

2. Multidrug and Extensively Drug Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response 2010;World Health Organization,2010

3. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps;O’Brien;Am. J. Respir. Crit. Care Med.,2001

4. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades;Spigelman;Int. J. Tuberc. Lung Dis.,2010

5. Tuberculosis: the role of risk factors and social determinants;Lonnroth,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo quantification and pharmacokinetic studies of cotinine in mice after smoke exposure by LC–MS/MS;Biomedical Chromatography;2019-12-29

2. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model;Journal of Medicinal Chemistry;2017-12-05

3. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 – A potential oral treatment for tuberculosis;Pulmonary Pharmacology & Therapeutics;2016-10